Summary of Jasper Therapeutics Chronic Urticaria Data Update Webinar Company Overview - **Company**: Jasper Therapeutics (NasdaqCM: JSPR) - **Focus**: Development of briquilimab for chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU) Key Points and Arguments Industry and Product Development - **Briquilimab**: An antibody targeting the KIT receptor, showing promise in treating mast cell-driven diseases, including CSU and CIndU [4][5] - **Clinical Trials**: Updated data from the BEACON study and an open-label extension study were presented, indicating positive outcomes for briquilimab [4][5] Efficacy and Safety Data - **BEACON Study Results**: - Six out of eight patients receiving briquilimab achieved complete response (CR) by week three, and four out of six by week 12 [6][9] - Mean reduction of UAS7 scores was 31 points at week 12, indicating significant symptom relief [9][12] - Rapid onset of disease control was observed, with most patients showing improvement within two weeks [9][10] - **Open-Label Extension Study**: - 63 patients treated with briquilimab showed durable clinical responses, with 65% of CIndU patients achieving CR or partial response (PR) at week 16 [9][15] - A favorable chronic safety profile was reported, with low incidence of KIT-related adverse events [7][20] Future Plans - **Phase 2b Study**: - Expected to commence in the second half of 2026, involving 75 to 100 adult patients with CSU [8][20] - The study will evaluate two effective dose regimens versus placebo [20] - **Dose Selection**: - Ongoing analysis of current data will inform the final dose selection for the phase 2b study [24][55] - Consideration of weight-adjusted dosing to optimize efficacy [48][55] Competitive Positioning - **Differentiated Product Profile**: - Briquilimab's unique mechanism of action and favorable safety profile position it competitively against other therapies targeting the KIT receptor [18][19] - The company believes the data supports a compelling product profile for chronic urticarias [20] Financial Considerations - **Capital Requirements**: - Current capital is sufficient to support operations through mid-2026, but additional funding will be necessary for future studies [28] - **Partnership Opportunities**: - The company is open to potential partnerships to support broader development across multiple indications [34] Additional Important Information - **CEO Transition**: The change in leadership was driven by the need for a new direction as the company progresses into pivotal studies [24] - **Regulatory Considerations**: The company is preparing to engage with regulatory bodies regarding the phase 2b study design and dose selection [25][46] This summary encapsulates the critical insights from the Jasper Therapeutics webinar, highlighting the company's advancements in chronic urticaria treatment and future strategic directions.

Core Insights - Jasper Therapeutics reported positive clinical data for briquilimab, an antibody therapy targeting KIT for chronic spontaneous urticaria (CSU) and other mast cell-driven diseases [2][3][11] BEACON Study Results - In the BEACON study, 67% of additional patients (n=6) achieved a complete response at 12 weeks, with a mean UAS7 reduction of 31 points [1][5] - 83% of participants in the 240mg/180mg Q8W cohort achieved a complete response by week 3 [2][5] - The study is a randomized, double-blind, placebo-controlled Phase 1b/2a trial focusing on safety, tolerability, and clinical activity [4] Open Label Extension Study Results - In the open-label extension study, 58% of CSU participants (n=36) achieved a complete response at 12 weeks, and 75% achieved either a complete response or well-controlled disease [9][10] - The study included a median follow-up duration of 205 days for 63 patients, with no dose-limiting toxicities observed [10] Safety Profile - Briquilimab was well-tolerated in both studies, with low-frequency, low-grade adverse events related to KIT blockade, none resulting in discontinuations [6][10] Future Plans - The data from the BEACON and open-label extension studies are deemed sufficient to support dose selection for a planned Phase 2b study in CSU, expected to commence in the second half of 2026 [11]